Mcm Polimedica 2 Sp. z o.o.

Researchers at Mcm Polimedica 2 are studying Chronic Heart Failure With Reduced Ejection Fraction to determine whether a new oral agent can lower the risk of cardiovascular death and heart‑failure hospitalization.

• Heart failure outcome measures
• Risk reduction strategies
• Innovative oral therapies

The trial involves a multidisciplinary team of 11 investigators and aims to improve long‑term survival for patients with severe cardiac dysfunction.

A study focusing on Chronic Obstructive Pulmonary Disease (COPD) evaluates the impact of benralizumab on reducing frequent exacerbations in patients with high peripheral blood eosinophils.

• Exacerbation frequency reduction
• Eosinophil‑guided treatment
• Management of severe COPD

Conducted at the Warsaw clinic, this research seeks to provide a targeted biologic option for individuals with a history of severe COPD attacks.

The site is evaluating povorcitinib in adults with Chronic Spontaneous Urticaria to assess its ability to control persistent hives and improve patient quality of life.

• Urticaria symptom control
• JAK inhibitor efficacy
• Quality‑of‑life outcomes

This trial adds to the limited therapeutic options for chronic hives and involves collaboration among dermatology specialists at the facility.